Published in Medical Letter on the CDC and FDA, August 20th, 2006
Gestiva, a long acting form of a naturally occurring progesterone, is the company's drug candidate to prevent preterm birth in women with a history of preterm delivery.
"The setting of an advisory committee meeting date marks an important next step in the Gestiva NDA review process," said Emory V. Anderson, president and chief executive officer. "A preterm birth occurs nearly every minute and imposes a $26 billion annual cost to the U.S. healthcare system. For the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.